nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—KIT—germ cell cancer	0.403	1	CbGaD
Nilotinib—UGT1A1—Etoposide—germ cell cancer	0.0313	0.125	CbGbCtD
Nilotinib—ABCG2—Dactinomycin—germ cell cancer	0.0305	0.122	CbGbCtD
Nilotinib—CYP2B6—Ifosfamide—germ cell cancer	0.0253	0.101	CbGbCtD
Nilotinib—CYP2C8—Ifosfamide—germ cell cancer	0.0192	0.0766	CbGbCtD
Nilotinib—ABCG2—Cisplatin—germ cell cancer	0.0175	0.07	CbGbCtD
Nilotinib—ABCG2—Etoposide—germ cell cancer	0.0172	0.0687	CbGbCtD
Nilotinib—CYP2C9—Ifosfamide—germ cell cancer	0.0134	0.0534	CbGbCtD
Nilotinib—CYP2B6—Cisplatin—germ cell cancer	0.0123	0.0492	CbGbCtD
Nilotinib—ABCG2—Methotrexate—germ cell cancer	0.0114	0.0454	CbGbCtD
Nilotinib—ABCB1—Dactinomycin—germ cell cancer	0.011	0.0439	CbGbCtD
Nilotinib—CYP2C8—Etoposide—germ cell cancer	0.00916	0.0366	CbGbCtD
Nilotinib—CYP3A4—Ifosfamide—germ cell cancer	0.00778	0.0311	CbGbCtD
Nilotinib—ABCB1—Vinblastine—germ cell cancer	0.00688	0.0275	CbGbCtD
Nilotinib—CYP2C9—Cisplatin—germ cell cancer	0.0065	0.026	CbGbCtD
Nilotinib—CYP2D6—Vinblastine—germ cell cancer	0.00649	0.0259	CbGbCtD
Nilotinib—ABCB1—Cisplatin—germ cell cancer	0.00631	0.0252	CbGbCtD
Nilotinib—ABCB1—Etoposide—germ cell cancer	0.0062	0.0248	CbGbCtD
Nilotinib—CYP3A4—Vinblastine—germ cell cancer	0.00412	0.0165	CbGbCtD
Nilotinib—ABCB1—Methotrexate—germ cell cancer	0.0041	0.0164	CbGbCtD
Nilotinib—CYP3A4—Etoposide—germ cell cancer	0.00372	0.0149	CbGbCtD
Nilotinib—Ponatinib—FGFR3—germ cell cancer	0.0034	0.58	CrCbGaD
Nilotinib—Ponatinib—KIT—germ cell cancer	0.00152	0.26	CrCbGaD
Nilotinib—Imatinib—KIT—germ cell cancer	0.000938	0.16	CrCbGaD
Nilotinib—MAP4K1—lymph node—germ cell cancer	0.000164	0.0014	CbGeAlD
Nilotinib—KIT—decidua—germ cell cancer	0.000164	0.0014	CbGeAlD
Nilotinib—MAPK14—head—germ cell cancer	0.000164	0.0014	CbGeAlD
Nilotinib—EPHB6—midbrain—germ cell cancer	0.000164	0.0014	CbGeAlD
Nilotinib—ABL1—retina—germ cell cancer	0.000163	0.0014	CbGeAlD
Nilotinib—FGR—head—germ cell cancer	0.000163	0.0014	CbGeAlD
Nilotinib—CA9—testis—germ cell cancer	0.000162	0.00139	CbGeAlD
Nilotinib—TIE1—brain—germ cell cancer	0.000162	0.00139	CbGeAlD
Nilotinib—TEK—female gonad—germ cell cancer	0.000162	0.00139	CbGeAlD
Nilotinib—PDGFRB—skin of body—germ cell cancer	0.000161	0.00138	CbGeAlD
Nilotinib—PDGFRB—decidua—germ cell cancer	0.00016	0.00137	CbGeAlD
Nilotinib—EPHB6—spinal cord—germ cell cancer	0.00016	0.00137	CbGeAlD
Nilotinib—CSF1R—gonad—germ cell cancer	0.000159	0.00136	CbGeAlD
Nilotinib—MAP2K5—pituitary gland—germ cell cancer	0.000159	0.00136	CbGeAlD
Nilotinib—EPHA4—cerebellum—germ cell cancer	0.000158	0.00136	CbGeAlD
Nilotinib—MAPK14—testis—germ cell cancer	0.000158	0.00135	CbGeAlD
Nilotinib—CA1—telencephalon—germ cell cancer	0.000158	0.00135	CbGeAlD
Nilotinib—CSF1R—uterus—germ cell cancer	0.000158	0.00135	CbGeAlD
Nilotinib—FGR—testis—germ cell cancer	0.000157	0.00135	CbGeAlD
Nilotinib—LCK—testis—germ cell cancer	0.000157	0.00135	CbGeAlD
Nilotinib—EPHB4—endocrine gland—germ cell cancer	0.000157	0.00135	CbGeAlD
Nilotinib—PDGFRA—adrenal gland—germ cell cancer	0.000157	0.00135	CbGeAlD
Nilotinib—TIE1—lymph node—germ cell cancer	0.000156	0.00134	CbGeAlD
Nilotinib—BRAF—brain—germ cell cancer	0.000155	0.00133	CbGeAlD
Nilotinib—CSF1R—pituitary gland—germ cell cancer	0.000155	0.00133	CbGeAlD
Nilotinib—EPHB6—female gonad—germ cell cancer	0.000155	0.00132	CbGeAlD
Nilotinib—EPHA2—endocrine gland—germ cell cancer	0.000154	0.00132	CbGeAlD
Nilotinib—EPHB3—brain—germ cell cancer	0.000154	0.00132	CbGeAlD
Nilotinib—MAP2K5—medulla oblongata—germ cell cancer	0.000153	0.00131	CbGeAlD
Nilotinib—EPHA2—head—germ cell cancer	0.000152	0.0013	CbGeAlD
Nilotinib—PDGFRA—spinal cord—germ cell cancer	0.000151	0.0013	CbGeAlD
Nilotinib—CA2—neck—germ cell cancer	0.000151	0.00129	CbGeAlD
Nilotinib—TEK—endocrine gland—germ cell cancer	0.00015	0.00129	CbGeAlD
Nilotinib—ABL1—telencephalon—germ cell cancer	0.00015	0.00129	CbGeAlD
Nilotinib—BRAF—lymph node—germ cell cancer	0.00015	0.00128	CbGeAlD
Nilotinib—EPHB4—testis—germ cell cancer	0.00015	0.00128	CbGeAlD
Nilotinib—CA9—cerebellum—germ cell cancer	0.00015	0.00128	CbGeAlD
Nilotinib—CSF1R—medulla oblongata—germ cell cancer	0.000149	0.00128	CbGeAlD
Nilotinib—EPHB3—lymph node—germ cell cancer	0.000149	0.00127	CbGeAlD
Nilotinib—TEK—head—germ cell cancer	0.000148	0.00127	CbGeAlD
Nilotinib—EPHA2—testis—germ cell cancer	0.000147	0.00126	CbGeAlD
Nilotinib—PDGFRA—female gonad—germ cell cancer	0.000147	0.00126	CbGeAlD
Nilotinib—MAPK14—cerebellum—germ cell cancer	0.000146	0.00125	CbGeAlD
Nilotinib—KIT—gonad—germ cell cancer	0.000144	0.00123	CbGeAlD
Nilotinib—ABL1—skin of body—germ cell cancer	0.000143	0.00123	CbGeAlD
Nilotinib—TEK—testis—germ cell cancer	0.000143	0.00123	CbGeAlD
Nilotinib—KIT—uterus—germ cell cancer	0.000143	0.00123	CbGeAlD
Nilotinib—ABL1—decidua—germ cell cancer	0.000142	0.00122	CbGeAlD
Nilotinib—CA14—cerebellum—germ cell cancer	0.000142	0.00122	CbGeAlD
Nilotinib—EPHB6—head—germ cell cancer	0.000142	0.00122	CbGeAlD
Nilotinib—MAP2K5—adrenal gland—germ cell cancer	0.000142	0.00121	CbGeAlD
Nilotinib—HCK—brain—germ cell cancer	0.000142	0.00121	CbGeAlD
Nilotinib—PDGFRB—gonad—germ cell cancer	0.000141	0.00121	CbGeAlD
Nilotinib—ABL2—brain—germ cell cancer	0.000141	0.0012	CbGeAlD
Nilotinib—KIT—pituitary gland—germ cell cancer	0.000141	0.0012	CbGeAlD
Nilotinib—MAP2K5—midbrain—germ cell cancer	0.00014	0.0012	CbGeAlD
Nilotinib—PDGFRB—uterus—germ cell cancer	0.00014	0.0012	CbGeAlD
Nilotinib—CA4—brainstem—germ cell cancer	0.000139	0.00119	CbGeAlD
Nilotinib—CA7—brain—germ cell cancer	0.000138	0.00119	CbGeAlD
Nilotinib—EPHB4—cerebellum—germ cell cancer	0.000138	0.00119	CbGeAlD
Nilotinib—CSF1R—adrenal gland—germ cell cancer	0.000138	0.00118	CbGeAlD
Nilotinib—PDGFRB—pituitary gland—germ cell cancer	0.000137	0.00118	CbGeAlD
Nilotinib—EPHB6—testis—germ cell cancer	0.000137	0.00117	CbGeAlD
Nilotinib—HCK—lymph node—germ cell cancer	0.000137	0.00117	CbGeAlD
Nilotinib—CSF1R—midbrain—germ cell cancer	0.000137	0.00117	CbGeAlD
Nilotinib—MAP2K5—spinal cord—germ cell cancer	0.000137	0.00117	CbGeAlD
Nilotinib—PDGFRA—endocrine gland—germ cell cancer	0.000136	0.00117	CbGeAlD
Nilotinib—ABL2—lymph node—germ cell cancer	0.000136	0.00116	CbGeAlD
Nilotinib—KIT—medulla oblongata—germ cell cancer	0.000136	0.00116	CbGeAlD
Nilotinib—PDGFRA—head—germ cell cancer	0.000135	0.00115	CbGeAlD
Nilotinib—CSF1R—bone marrow—germ cell cancer	0.000134	0.00115	CbGeAlD
Nilotinib—CSF1R—spinal cord—germ cell cancer	0.000133	0.00114	CbGeAlD
Nilotinib—PDGFRB—medulla oblongata—germ cell cancer	0.000133	0.00114	CbGeAlD
Nilotinib—TEK—cerebellum—germ cell cancer	0.000132	0.00113	CbGeAlD
Nilotinib—MAP2K5—female gonad—germ cell cancer	0.000132	0.00113	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Bleomycin—germ cell cancer	0.000131	0.00112	CcSEcCtD
Nilotinib—Hypertension—Ifosfamide—germ cell cancer	0.00013	0.00111	CcSEcCtD
Nilotinib—CA2—trigeminal ganglion—germ cell cancer	0.00013	0.00112	CbGeAlD
Nilotinib—Malnutrition—Cisplatin—germ cell cancer	0.00013	0.00111	CcSEcCtD
Nilotinib—Erythema—Cisplatin—germ cell cancer	0.00013	0.00111	CcSEcCtD
Nilotinib—UGT1A1—endocrine gland—germ cell cancer	0.00013	0.00111	CbGeAlD
Nilotinib—PDGFRA—testis—germ cell cancer	0.00013	0.00111	CbGeAlD
Nilotinib—Erythema multiforme—Etoposide—germ cell cancer	0.00013	0.0011	CcSEcCtD
Nilotinib—Paraesthesia—Bleomycin—germ cell cancer	0.00013	0.0011	CcSEcCtD
Nilotinib—CSF1R—female gonad—germ cell cancer	0.000129	0.0011	CbGeAlD
Nilotinib—EPHA4—brain—germ cell cancer	0.000129	0.0011	CbGeAlD
Nilotinib—Dyspnoea—Bleomycin—germ cell cancer	0.000129	0.00109	CcSEcCtD
Nilotinib—Arthralgia—Ifosfamide—germ cell cancer	0.000129	0.00109	CcSEcCtD
Nilotinib—Myalgia—Ifosfamide—germ cell cancer	0.000129	0.00109	CcSEcCtD
Nilotinib—Chest pain—Ifosfamide—germ cell cancer	0.000129	0.00109	CcSEcCtD
Nilotinib—Flatulence—Cisplatin—germ cell cancer	0.000128	0.00109	CcSEcCtD
Nilotinib—Anorexia—Dactinomycin—germ cell cancer	0.000128	0.00109	CcSEcCtD
Nilotinib—Eye disorder—Etoposide—germ cell cancer	0.000128	0.00109	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.000128	0.00108	CcSEcCtD
Nilotinib—Flushing—Etoposide—germ cell cancer	0.000127	0.00108	CcSEcCtD
Nilotinib—Cardiac disorder—Etoposide—germ cell cancer	0.000127	0.00108	CcSEcCtD
Nilotinib—Discomfort—Ifosfamide—germ cell cancer	0.000127	0.00108	CcSEcCtD
Nilotinib—CA3—brain—germ cell cancer	0.000127	0.00109	CbGeAlD
Nilotinib—EPHB6—cerebellum—germ cell cancer	0.000127	0.00108	CbGeAlD
Nilotinib—CA2—embryo—germ cell cancer	0.000126	0.00108	CbGeAlD
Nilotinib—Hypersensitivity—Vinblastine—germ cell cancer	0.000126	0.00107	CcSEcCtD
Nilotinib—CA12—endocrine gland—germ cell cancer	0.000126	0.00108	CbGeAlD
Nilotinib—KIT—adrenal gland—germ cell cancer	0.000126	0.00108	CbGeAlD
Nilotinib—ABL1—gonad—germ cell cancer	0.000125	0.00107	CbGeAlD
Nilotinib—Decreased appetite—Bleomycin—germ cell cancer	0.000125	0.00106	CcSEcCtD
Nilotinib—Muscle spasms—Cisplatin—germ cell cancer	0.000125	0.00106	CcSEcCtD
Nilotinib—ABL1—uterus—germ cell cancer	0.000125	0.00107	CbGeAlD
Nilotinib—Angiopathy—Etoposide—germ cell cancer	0.000124	0.00106	CcSEcCtD
Nilotinib—Confusional state—Ifosfamide—germ cell cancer	0.000124	0.00106	CcSEcCtD
Nilotinib—EPHA4—lymph node—germ cell cancer	0.000124	0.00106	CbGeAlD
Nilotinib—CA12—head—germ cell cancer	0.000124	0.00106	CbGeAlD
Nilotinib—KIT—midbrain—germ cell cancer	0.000124	0.00106	CbGeAlD
Nilotinib—Immune system disorder—Etoposide—germ cell cancer	0.000124	0.00105	CcSEcCtD
Nilotinib—Mediastinal disorder—Etoposide—germ cell cancer	0.000123	0.00105	CcSEcCtD
Nilotinib—CA4—telencephalon—germ cell cancer	0.000123	0.00106	CbGeAlD
Nilotinib—Pain—Bleomycin—germ cell cancer	0.000123	0.00105	CcSEcCtD
Nilotinib—Oedema—Ifosfamide—germ cell cancer	0.000123	0.00105	CcSEcCtD
Nilotinib—Chills—Etoposide—germ cell cancer	0.000123	0.00104	CcSEcCtD
Nilotinib—MAP2K5—endocrine gland—germ cell cancer	0.000123	0.00105	CbGeAlD
Nilotinib—CA3—lymph node—germ cell cancer	0.000123	0.00105	CbGeAlD
Nilotinib—Vision blurred—Cisplatin—germ cell cancer	0.000123	0.00104	CcSEcCtD
Nilotinib—PDGFRB—adrenal gland—germ cell cancer	0.000123	0.00105	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.000123	0.00104	CcSEcCtD
Nilotinib—Asthenia—Vinblastine—germ cell cancer	0.000123	0.00104	CcSEcCtD
Nilotinib—Infection—Ifosfamide—germ cell cancer	0.000122	0.00104	CcSEcCtD
Nilotinib—ABL1—pituitary gland—germ cell cancer	0.000122	0.00105	CbGeAlD
Nilotinib—Tremor—Cisplatin—germ cell cancer	0.000122	0.00104	CcSEcCtD
Nilotinib—KIT—bone marrow—germ cell cancer	0.000122	0.00104	CbGeAlD
Nilotinib—MAP2K5—head—germ cell cancer	0.000121	0.00104	CbGeAlD
Nilotinib—PDGFRB—midbrain—germ cell cancer	0.000121	0.00104	CbGeAlD
Nilotinib—Alopecia—Etoposide—germ cell cancer	0.000121	0.00103	CcSEcCtD
Nilotinib—Lethargy—Methotrexate—germ cell cancer	0.000121	0.00103	CcSEcCtD
Nilotinib—KIT—spinal cord—germ cell cancer	0.000121	0.00104	CbGeAlD
Nilotinib—Nervous system disorder—Ifosfamide—germ cell cancer	0.000121	0.00103	CcSEcCtD
Nilotinib—Ill-defined disorder—Cisplatin—germ cell cancer	0.000121	0.00103	CcSEcCtD
Nilotinib—ABCG2—trigeminal ganglion—germ cell cancer	0.000121	0.00103	CbGeAlD
Nilotinib—Thrombocytopenia—Ifosfamide—germ cell cancer	0.000121	0.00102	CcSEcCtD
Nilotinib—Anaemia—Cisplatin—germ cell cancer	0.00012	0.00102	CcSEcCtD
Nilotinib—PDGFRA—cerebellum—germ cell cancer	0.00012	0.00103	CbGeAlD
Nilotinib—CSF1R—endocrine gland—germ cell cancer	0.00012	0.00103	CbGeAlD
Nilotinib—Skin disorder—Ifosfamide—germ cell cancer	0.00012	0.00102	CcSEcCtD
Nilotinib—Hyperhidrosis—Ifosfamide—germ cell cancer	0.000119	0.00101	CcSEcCtD
Nilotinib—Feeling abnormal—Bleomycin—germ cell cancer	0.000119	0.00101	CcSEcCtD
Nilotinib—PDGFRB—bone marrow—germ cell cancer	0.000119	0.00102	CbGeAlD
Nilotinib—MAPK14—brain—germ cell cancer	0.000119	0.00102	CbGeAlD
Nilotinib—CSF1R—head—germ cell cancer	0.000118	0.00101	CbGeAlD
Nilotinib—PDGFRB—spinal cord—germ cell cancer	0.000118	0.00101	CbGeAlD
Nilotinib—ABL1—medulla oblongata—germ cell cancer	0.000118	0.00101	CbGeAlD
Nilotinib—FGR—brain—germ cell cancer	0.000118	0.00101	CbGeAlD
Nilotinib—Anorexia—Ifosfamide—germ cell cancer	0.000117	0.000997	CcSEcCtD
Nilotinib—Malaise—Cisplatin—germ cell cancer	0.000117	0.000997	CcSEcCtD
Nilotinib—MAP2K5—testis—germ cell cancer	0.000117	0.001	CbGeAlD
Nilotinib—KIT—female gonad—germ cell cancer	0.000117	0.001	CbGeAlD
Nilotinib—Decreased appetite—Dactinomycin—germ cell cancer	0.000117	0.000993	CcSEcCtD
Nilotinib—Diarrhoea—Vinblastine—germ cell cancer	0.000117	0.000992	CcSEcCtD
Nilotinib—Dysgeusia—Etoposide—germ cell cancer	0.000117	0.000992	CcSEcCtD
Nilotinib—Leukopenia—Cisplatin—germ cell cancer	0.000117	0.000989	CcSEcCtD
Nilotinib—Fatigue—Dactinomycin—germ cell cancer	0.000116	0.000984	CcSEcCtD
Nilotinib—Back pain—Etoposide—germ cell cancer	0.000115	0.000979	CcSEcCtD
Nilotinib—CA14—brain—germ cell cancer	0.000115	0.000988	CbGeAlD
Nilotinib—CA2—brainstem—germ cell cancer	0.000115	0.000988	CbGeAlD
Nilotinib—Hypotension—Ifosfamide—germ cell cancer	0.000115	0.000978	CcSEcCtD
Nilotinib—Pain—Dactinomycin—germ cell cancer	0.000115	0.000976	CcSEcCtD
Nilotinib—Muscle spasms—Etoposide—germ cell cancer	0.000115	0.000974	CcSEcCtD
Nilotinib—MAPK14—lymph node—germ cell cancer	0.000115	0.000982	CbGeAlD
Nilotinib—Urticaria—Bleomycin—germ cell cancer	0.000115	0.000973	CcSEcCtD
Nilotinib—CSF1R—testis—germ cell cancer	0.000114	0.00098	CbGeAlD
Nilotinib—PDGFRB—female gonad—germ cell cancer	0.000114	0.00098	CbGeAlD
Nilotinib—LCK—lymph node—germ cell cancer	0.000114	0.000978	CbGeAlD
Nilotinib—FGR—lymph node—germ cell cancer	0.000114	0.000978	CbGeAlD
Nilotinib—Body temperature increased—Bleomycin—germ cell cancer	0.000114	0.000968	CcSEcCtD
Nilotinib—Dizziness—Vinblastine—germ cell cancer	0.000113	0.000959	CcSEcCtD
Nilotinib—EPHB4—brain—germ cell cancer	0.000112	0.000963	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.000112	0.000953	CcSEcCtD
Nilotinib—CA2—eye—germ cell cancer	0.000112	0.000962	CbGeAlD
Nilotinib—CA2—retina—germ cell cancer	0.000111	0.000953	CbGeAlD
Nilotinib—CA1—bone marrow—germ cell cancer	0.000111	0.000952	CbGeAlD
Nilotinib—Myalgia—Cisplatin—germ cell cancer	0.000111	0.000941	CcSEcCtD
Nilotinib—Feeling abnormal—Dactinomycin—germ cell cancer	0.000111	0.000941	CcSEcCtD
Nilotinib—Paraesthesia—Ifosfamide—germ cell cancer	0.000111	0.00094	CcSEcCtD
Nilotinib—Ill-defined disorder—Etoposide—germ cell cancer	0.000111	0.00094	CcSEcCtD
Nilotinib—CA1—spinal cord—germ cell cancer	0.000111	0.000948	CbGeAlD
Nilotinib—Anxiety—Cisplatin—germ cell cancer	0.00011	0.000938	CcSEcCtD
Nilotinib—EPHA2—brain—germ cell cancer	0.00011	0.000945	CbGeAlD
Nilotinib—Anaemia—Etoposide—germ cell cancer	0.00011	0.000936	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.00011	0.000935	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dactinomycin—germ cell cancer	0.00011	0.000934	CcSEcCtD
Nilotinib—Dyspnoea—Ifosfamide—germ cell cancer	0.00011	0.000933	CcSEcCtD
Nilotinib—Discomfort—Cisplatin—germ cell cancer	0.00011	0.00093	CcSEcCtD
Nilotinib—ABL1—adrenal gland—germ cell cancer	0.000109	0.000937	CbGeAlD
Nilotinib—KIT—endocrine gland—germ cell cancer	0.000109	0.000933	CbGeAlD
Nilotinib—EPHB4—lymph node—germ cell cancer	0.000109	0.000931	CbGeAlD
Nilotinib—Vomiting—Vinblastine—germ cell cancer	0.000109	0.000922	CcSEcCtD
Nilotinib—MAP2K5—cerebellum—germ cell cancer	0.000108	0.000927	CbGeAlD
Nilotinib—ABL1—midbrain—germ cell cancer	0.000108	0.000925	CbGeAlD
Nilotinib—TEK—brain—germ cell cancer	0.000108	0.000922	CbGeAlD
Nilotinib—Malaise—Etoposide—germ cell cancer	0.000108	0.000913	CcSEcCtD
Nilotinib—KIT—head—germ cell cancer	0.000108	0.000921	CbGeAlD
Nilotinib—Breast disorder—Methotrexate—germ cell cancer	0.000107	0.00091	CcSEcCtD
Nilotinib—Vertigo—Etoposide—germ cell cancer	0.000107	0.00091	CcSEcCtD
Nilotinib—Decreased appetite—Ifosfamide—germ cell cancer	0.000107	0.00091	CcSEcCtD
Nilotinib—Headache—Vinblastine—germ cell cancer	0.000107	0.000908	CcSEcCtD
Nilotinib—Leukopenia—Etoposide—germ cell cancer	0.000107	0.000906	CcSEcCtD
Nilotinib—EPHA2—lymph node—germ cell cancer	0.000107	0.000913	CbGeAlD
Nilotinib—Gastrointestinal disorder—Ifosfamide—germ cell cancer	0.000106	0.000903	CcSEcCtD
Nilotinib—PDGFRB—endocrine gland—germ cell cancer	0.000106	0.000911	CbGeAlD
Nilotinib—Abdominal pain—Dactinomycin—germ cell cancer	0.000106	0.000903	CcSEcCtD
Nilotinib—Body temperature increased—Dactinomycin—germ cell cancer	0.000106	0.000903	CcSEcCtD
Nilotinib—Fatigue—Ifosfamide—germ cell cancer	0.000106	0.000902	CcSEcCtD
Nilotinib—Oedema—Cisplatin—germ cell cancer	0.000106	0.000902	CcSEcCtD
Nilotinib—Hypersensitivity—Bleomycin—germ cell cancer	0.000106	0.000902	CcSEcCtD
Nilotinib—ABL1—bone marrow—germ cell cancer	0.000106	0.000906	CbGeAlD
Nilotinib—CSF1R—cerebellum—germ cell cancer	0.000106	0.000905	CbGeAlD
Nilotinib—Infection—Cisplatin—germ cell cancer	0.000106	0.000896	CcSEcCtD
Nilotinib—Pain—Ifosfamide—germ cell cancer	0.000105	0.000895	CcSEcCtD
Nilotinib—Constipation—Ifosfamide—germ cell cancer	0.000105	0.000895	CcSEcCtD
Nilotinib—ABL1—spinal cord—germ cell cancer	0.000105	0.000902	CbGeAlD
Nilotinib—PDGFRB—head—germ cell cancer	0.000105	0.0009	CbGeAlD
Nilotinib—Loss of consciousness—Etoposide—germ cell cancer	0.000105	0.00089	CcSEcCtD
Nilotinib—Nervous system disorder—Cisplatin—germ cell cancer	0.000104	0.000885	CcSEcCtD
Nilotinib—Cough—Etoposide—germ cell cancer	0.000104	0.000884	CcSEcCtD
Nilotinib—Thrombocytopenia—Cisplatin—germ cell cancer	0.000104	0.000883	CcSEcCtD
Nilotinib—TEK—lymph node—germ cell cancer	0.000104	0.000891	CbGeAlD
Nilotinib—KIT—testis—germ cell cancer	0.000104	0.00089	CbGeAlD
Nilotinib—Tachycardia—Cisplatin—germ cell cancer	0.000104	0.00088	CcSEcCtD
Nilotinib—Asthenia—Bleomycin—germ cell cancer	0.000103	0.000878	CcSEcCtD
Nilotinib—Skin disorder—Cisplatin—germ cell cancer	0.000103	0.000876	CcSEcCtD
Nilotinib—Hypertension—Etoposide—germ cell cancer	0.000103	0.000874	CcSEcCtD
Nilotinib—EPHB6—brain—germ cell cancer	0.000103	0.000881	CbGeAlD
Nilotinib—Hyperhidrosis—Cisplatin—germ cell cancer	0.000103	0.000872	CcSEcCtD
Nilotinib—CA2—telencephalon—germ cell cancer	0.000102	0.000877	CbGeAlD
Nilotinib—Pruritus—Bleomycin—germ cell cancer	0.000102	0.000866	CcSEcCtD
Nilotinib—ABL1—female gonad—germ cell cancer	0.000102	0.000873	CbGeAlD
Nilotinib—Feeling abnormal—Ifosfamide—germ cell cancer	0.000102	0.000862	CcSEcCtD
Nilotinib—Chest pain—Etoposide—germ cell cancer	0.000102	0.000862	CcSEcCtD
Nilotinib—Eosinophilia—Methotrexate—germ cell cancer	0.000102	0.000862	CcSEcCtD
Nilotinib—PDGFRB—testis—germ cell cancer	0.000101	0.000869	CbGeAlD
Nilotinib—Nausea—Vinblastine—germ cell cancer	0.000101	0.000861	CcSEcCtD
Nilotinib—Anorexia—Cisplatin—germ cell cancer	0.000101	0.00086	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	0.000101	0.000856	CcSEcCtD
Nilotinib—Gastrointestinal pain—Ifosfamide—germ cell cancer	0.000101	0.000856	CcSEcCtD
Nilotinib—Pancreatitis—Methotrexate—germ cell cancer	0.000101	0.000853	CcSEcCtD
Nilotinib—CA4—pituitary gland—germ cell cancer	0.000101	0.000861	CbGeAlD
Nilotinib—Discomfort—Etoposide—germ cell cancer	0.0001	0.000852	CcSEcCtD
Nilotinib—CA1—endocrine gland—germ cell cancer	9.96e-05	0.000853	CbGeAlD
Nilotinib—EPHB6—lymph node—germ cell cancer	9.94e-05	0.000851	CbGeAlD
Nilotinib—Hypotension—Cisplatin—germ cell cancer	9.93e-05	0.000843	CcSEcCtD
Nilotinib—Hypersensitivity—Dactinomycin—germ cell cancer	9.91e-05	0.000841	CcSEcCtD
Nilotinib—CA1—head—germ cell cancer	9.83e-05	0.000843	CbGeAlD
Nilotinib—Abdominal discomfort—Methotrexate—germ cell cancer	9.83e-05	0.000834	CcSEcCtD
Nilotinib—Confusional state—Etoposide—germ cell cancer	9.82e-05	0.000833	CcSEcCtD
Nilotinib—Urticaria—Ifosfamide—germ cell cancer	9.79e-05	0.000831	CcSEcCtD
Nilotinib—CA2—skin of body—germ cell cancer	9.77e-05	0.000837	CbGeAlD
Nilotinib—PDGFRA—brain—germ cell cancer	9.75e-05	0.000835	CbGeAlD
Nilotinib—Body temperature increased—Ifosfamide—germ cell cancer	9.74e-05	0.000827	CcSEcCtD
Nilotinib—Abdominal pain—Ifosfamide—germ cell cancer	9.74e-05	0.000827	CcSEcCtD
Nilotinib—Pancytopenia—Methotrexate—germ cell cancer	9.74e-05	0.000827	CcSEcCtD
Nilotinib—CA2—decidua—germ cell cancer	9.7e-05	0.000831	CbGeAlD
Nilotinib—CA4—medulla oblongata—germ cell cancer	9.7e-05	0.000831	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Cisplatin—germ cell cancer	9.68e-05	0.000822	CcSEcCtD
Nilotinib—Infection—Etoposide—germ cell cancer	9.67e-05	0.000821	CcSEcCtD
Nilotinib—Asthenia—Dactinomycin—germ cell cancer	9.65e-05	0.000819	CcSEcCtD
Nilotinib—ABCB1—blood vessel—germ cell cancer	9.64e-05	0.000825	CbGeAlD
Nilotinib—KIT—cerebellum—germ cell cancer	9.59e-05	0.000822	CbGeAlD
Nilotinib—Dysuria—Methotrexate—germ cell cancer	9.59e-05	0.000814	CcSEcCtD
Nilotinib—Neutropenia—Methotrexate—germ cell cancer	9.59e-05	0.000814	CcSEcCtD
Nilotinib—Paraesthesia—Cisplatin—germ cell cancer	9.54e-05	0.00081	CcSEcCtD
Nilotinib—Thrombocytopenia—Etoposide—germ cell cancer	9.53e-05	0.000809	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Methotrexate—germ cell cancer	9.53e-05	0.000809	CcSEcCtD
Nilotinib—Tachycardia—Etoposide—germ cell cancer	9.5e-05	0.000807	CcSEcCtD
Nilotinib—ABL1—endocrine gland—germ cell cancer	9.48e-05	0.000812	CbGeAlD
Nilotinib—ABCG2—telencephalon—germ cell cancer	9.48e-05	0.000812	CbGeAlD
Nilotinib—Dyspnoea—Cisplatin—germ cell cancer	9.47e-05	0.000804	CcSEcCtD
Nilotinib—Skin disorder—Etoposide—germ cell cancer	9.46e-05	0.000803	CcSEcCtD
Nilotinib—Erectile dysfunction—Methotrexate—germ cell cancer	9.44e-05	0.000802	CcSEcCtD
Nilotinib—PDGFRA—lymph node—germ cell cancer	9.42e-05	0.000807	CbGeAlD
Nilotinib—Hyperhidrosis—Etoposide—germ cell cancer	9.41e-05	0.000799	CcSEcCtD
Nilotinib—PDGFRB—cerebellum—germ cell cancer	9.37e-05	0.000803	CbGeAlD
Nilotinib—ABL1—head—germ cell cancer	9.36e-05	0.000802	CbGeAlD
Nilotinib—Photosensitivity reaction—Methotrexate—germ cell cancer	9.36e-05	0.000795	CcSEcCtD
Nilotinib—Anorexia—Etoposide—germ cell cancer	9.28e-05	0.000788	CcSEcCtD
Nilotinib—Decreased appetite—Cisplatin—germ cell cancer	9.24e-05	0.000784	CcSEcCtD
Nilotinib—Diarrhoea—Dactinomycin—germ cell cancer	9.2e-05	0.000781	CcSEcCtD
Nilotinib—Pneumonia—Methotrexate—germ cell cancer	9.2e-05	0.000781	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Cisplatin—germ cell cancer	9.17e-05	0.000779	CcSEcCtD
Nilotinib—Vomiting—Bleomycin—germ cell cancer	9.17e-05	0.000778	CcSEcCtD
Nilotinib—Infestation NOS—Methotrexate—germ cell cancer	9.14e-05	0.000776	CcSEcCtD
Nilotinib—Infestation—Methotrexate—germ cell cancer	9.14e-05	0.000776	CcSEcCtD
Nilotinib—Hypotension—Etoposide—germ cell cancer	9.1e-05	0.000772	CcSEcCtD
Nilotinib—Rash—Bleomycin—germ cell cancer	9.09e-05	0.000772	CcSEcCtD
Nilotinib—Pain—Cisplatin—germ cell cancer	9.09e-05	0.000771	CcSEcCtD
Nilotinib—Dermatitis—Bleomycin—germ cell cancer	9.09e-05	0.000771	CcSEcCtD
Nilotinib—Hypersensitivity—Ifosfamide—germ cell cancer	9.08e-05	0.000771	CcSEcCtD
Nilotinib—ABL1—testis—germ cell cancer	9.04e-05	0.000775	CbGeAlD
Nilotinib—CA12—brain—germ cell cancer	9e-05	0.000771	CbGeAlD
Nilotinib—Renal failure—Methotrexate—germ cell cancer	8.99e-05	0.000763	CcSEcCtD
Nilotinib—ABCG2—decidua—germ cell cancer	8.99e-05	0.00077	CbGeAlD
Nilotinib—CA4—adrenal gland—germ cell cancer	8.98e-05	0.000769	CbGeAlD
Nilotinib—Stomatitis—Methotrexate—germ cell cancer	8.91e-05	0.000757	CcSEcCtD
Nilotinib—Conjunctivitis—Methotrexate—germ cell cancer	8.89e-05	0.000754	CcSEcCtD
Nilotinib—CA4—midbrain—germ cell cancer	8.87e-05	0.000759	CbGeAlD
Nilotinib—Asthenia—Ifosfamide—germ cell cancer	8.84e-05	0.000751	CcSEcCtD
Nilotinib—MAP2K5—brain—germ cell cancer	8.79e-05	0.000753	CbGeAlD
Nilotinib—Feeling abnormal—Cisplatin—germ cell cancer	8.76e-05	0.000743	CcSEcCtD
Nilotinib—Paraesthesia—Etoposide—germ cell cancer	8.74e-05	0.000742	CcSEcCtD
Nilotinib—Pruritus—Ifosfamide—germ cell cancer	8.72e-05	0.00074	CcSEcCtD
Nilotinib—Haematuria—Methotrexate—germ cell cancer	8.72e-05	0.00074	CcSEcCtD
Nilotinib—CA4—bone marrow—germ cell cancer	8.69e-05	0.000744	CbGeAlD
Nilotinib—Dyspnoea—Etoposide—germ cell cancer	8.68e-05	0.000737	CcSEcCtD
Nilotinib—CA4—spinal cord—germ cell cancer	8.65e-05	0.000741	CbGeAlD
Nilotinib—Hepatobiliary disease—Methotrexate—germ cell cancer	8.65e-05	0.000734	CcSEcCtD
Nilotinib—Epistaxis—Methotrexate—germ cell cancer	8.62e-05	0.000732	CcSEcCtD
Nilotinib—CSF1R—brain—germ cell cancer	8.58e-05	0.000735	CbGeAlD
Nilotinib—Nausea—Bleomycin—germ cell cancer	8.57e-05	0.000727	CcSEcCtD
Nilotinib—Vomiting—Dactinomycin—germ cell cancer	8.55e-05	0.000726	CcSEcCtD
Nilotinib—MAP2K5—lymph node—germ cell cancer	8.5e-05	0.000728	CbGeAlD
Nilotinib—Rash—Dactinomycin—germ cell cancer	8.48e-05	0.00072	CcSEcCtD
Nilotinib—Decreased appetite—Etoposide—germ cell cancer	8.46e-05	0.000718	CcSEcCtD
Nilotinib—Diarrhoea—Ifosfamide—germ cell cancer	8.43e-05	0.000716	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Etoposide—germ cell cancer	8.41e-05	0.000713	CcSEcCtD
Nilotinib—Body temperature increased—Cisplatin—germ cell cancer	8.4e-05	0.000713	CcSEcCtD
Nilotinib—Fatigue—Etoposide—germ cell cancer	8.39e-05	0.000712	CcSEcCtD
Nilotinib—CA4—female gonad—germ cell cancer	8.37e-05	0.000717	CbGeAlD
Nilotinib—ABL1—cerebellum—germ cell cancer	8.35e-05	0.000715	CbGeAlD
Nilotinib—CYP2B6—skin of body—germ cell cancer	8.35e-05	0.000715	CbGeAlD
Nilotinib—CA2—pituitary gland—germ cell cancer	8.33e-05	0.000714	CbGeAlD
Nilotinib—Pain—Etoposide—germ cell cancer	8.33e-05	0.000707	CcSEcCtD
Nilotinib—Constipation—Etoposide—germ cell cancer	8.33e-05	0.000707	CcSEcCtD
Nilotinib—CSF1R—lymph node—germ cell cancer	8.29e-05	0.00071	CbGeAlD
Nilotinib—Haemoglobin—Methotrexate—germ cell cancer	8.25e-05	0.0007	CcSEcCtD
Nilotinib—Haemorrhage—Methotrexate—germ cell cancer	8.21e-05	0.000697	CcSEcCtD
Nilotinib—Hepatitis—Methotrexate—germ cell cancer	8.21e-05	0.000697	CcSEcCtD
Nilotinib—Dizziness—Ifosfamide—germ cell cancer	8.15e-05	0.000692	CcSEcCtD
Nilotinib—Pharyngitis—Methotrexate—germ cell cancer	8.15e-05	0.000692	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—germ cell cancer	8.11e-05	0.000688	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—germ cell cancer	8.05e-05	0.000683	CcSEcCtD
Nilotinib—CA2—medulla oblongata—germ cell cancer	8.04e-05	0.000689	CbGeAlD
Nilotinib—Feeling abnormal—Etoposide—germ cell cancer	8.02e-05	0.000681	CcSEcCtD
Nilotinib—Nausea—Dactinomycin—germ cell cancer	7.99e-05	0.000678	CcSEcCtD
Nilotinib—Gastrointestinal pain—Etoposide—germ cell cancer	7.96e-05	0.000676	CcSEcCtD
Nilotinib—CYP2C8—pituitary gland—germ cell cancer	7.94e-05	0.00068	CbGeAlD
Nilotinib—Visual impairment—Methotrexate—germ cell cancer	7.91e-05	0.000671	CcSEcCtD
Nilotinib—ABCG2—uterus—germ cell cancer	7.86e-05	0.000673	CbGeAlD
Nilotinib—Vomiting—Ifosfamide—germ cell cancer	7.84e-05	0.000665	CcSEcCtD
Nilotinib—Hypersensitivity—Cisplatin—germ cell cancer	7.83e-05	0.000665	CcSEcCtD
Nilotinib—KIT—brain—germ cell cancer	7.79e-05	0.000668	CbGeAlD
Nilotinib—CA4—endocrine gland—germ cell cancer	7.79e-05	0.000667	CbGeAlD
Nilotinib—Rash—Ifosfamide—germ cell cancer	7.77e-05	0.00066	CcSEcCtD
Nilotinib—Dermatitis—Ifosfamide—germ cell cancer	7.76e-05	0.000659	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—germ cell cancer	7.76e-05	0.000659	CcSEcCtD
Nilotinib—Urticaria—Etoposide—germ cell cancer	7.73e-05	0.000657	CcSEcCtD
Nilotinib—ABCG2—pituitary gland—germ cell cancer	7.72e-05	0.000661	CbGeAlD
Nilotinib—Body temperature increased—Etoposide—germ cell cancer	7.7e-05	0.000653	CcSEcCtD
Nilotinib—Abdominal pain—Etoposide—germ cell cancer	7.7e-05	0.000653	CcSEcCtD
Nilotinib—CA4—head—germ cell cancer	7.69e-05	0.000659	CbGeAlD
Nilotinib—Eye disorder—Methotrexate—germ cell cancer	7.67e-05	0.000651	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—germ cell cancer	7.65e-05	0.00065	CcSEcCtD
Nilotinib—Asthenia—Cisplatin—germ cell cancer	7.62e-05	0.000647	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—germ cell cancer	7.62e-05	0.000647	CcSEcCtD
Nilotinib—PDGFRB—brain—germ cell cancer	7.61e-05	0.000652	CbGeAlD
Nilotinib—KIT—lymph node—germ cell cancer	7.53e-05	0.000645	CbGeAlD
Nilotinib—ABCG2—medulla oblongata—germ cell cancer	7.45e-05	0.000638	CbGeAlD
Nilotinib—Angiopathy—Methotrexate—germ cell cancer	7.45e-05	0.000632	CcSEcCtD
Nilotinib—CA2—adrenal gland—germ cell cancer	7.45e-05	0.000638	CbGeAlD
Nilotinib—CA4—testis—germ cell cancer	7.43e-05	0.000636	CbGeAlD
Nilotinib—Immune system disorder—Methotrexate—germ cell cancer	7.41e-05	0.000629	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—germ cell cancer	7.4e-05	0.000628	CcSEcCtD
Nilotinib—Chills—Methotrexate—germ cell cancer	7.36e-05	0.000625	CcSEcCtD
Nilotinib—PDGFRB—lymph node—germ cell cancer	7.35e-05	0.00063	CbGeAlD
Nilotinib—CA2—midbrain—germ cell cancer	7.35e-05	0.00063	CbGeAlD
Nilotinib—CYP2D6—brainstem—germ cell cancer	7.32e-05	0.000627	CbGeAlD
Nilotinib—Nausea—Ifosfamide—germ cell cancer	7.32e-05	0.000622	CcSEcCtD
Nilotinib—CYP2B6—gonad—germ cell cancer	7.3e-05	0.000625	CbGeAlD
Nilotinib—Diarrhoea—Cisplatin—germ cell cancer	7.27e-05	0.000617	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—germ cell cancer	7.25e-05	0.000616	CcSEcCtD
Nilotinib—CA2—bone marrow—germ cell cancer	7.2e-05	0.000617	CbGeAlD
Nilotinib—Mental disorder—Methotrexate—germ cell cancer	7.19e-05	0.00061	CcSEcCtD
Nilotinib—Hypersensitivity—Etoposide—germ cell cancer	7.17e-05	0.000609	CcSEcCtD
Nilotinib—CA2—spinal cord—germ cell cancer	7.17e-05	0.000614	CbGeAlD
Nilotinib—Malnutrition—Methotrexate—germ cell cancer	7.15e-05	0.000607	CcSEcCtD
Nilotinib—Erythema—Methotrexate—germ cell cancer	7.15e-05	0.000607	CcSEcCtD
Nilotinib—CA1—brain—germ cell cancer	7.13e-05	0.000611	CbGeAlD
Nilotinib—Dysgeusia—Methotrexate—germ cell cancer	7e-05	0.000594	CcSEcCtD
Nilotinib—Asthenia—Etoposide—germ cell cancer	6.99e-05	0.000593	CcSEcCtD
Nilotinib—CA2—female gonad—germ cell cancer	6.94e-05	0.000595	CbGeAlD
Nilotinib—Back pain—Methotrexate—germ cell cancer	6.91e-05	0.000587	CcSEcCtD
Nilotinib—ABCG2—adrenal gland—germ cell cancer	6.9e-05	0.000591	CbGeAlD
Nilotinib—Pruritus—Etoposide—germ cell cancer	6.89e-05	0.000585	CcSEcCtD
Nilotinib—CA1—lymph node—germ cell cancer	6.89e-05	0.00059	CbGeAlD
Nilotinib—CA4—cerebellum—germ cell cancer	6.86e-05	0.000588	CbGeAlD
Nilotinib—ABCG2—midbrain—germ cell cancer	6.81e-05	0.000583	CbGeAlD
Nilotinib—ABL1—brain—germ cell cancer	6.78e-05	0.000581	CbGeAlD
Nilotinib—Vomiting—Cisplatin—germ cell cancer	6.76e-05	0.000574	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—germ cell cancer	6.73e-05	0.000572	CcSEcCtD
Nilotinib—Rash—Cisplatin—germ cell cancer	6.7e-05	0.000569	CcSEcCtD
Nilotinib—Dermatitis—Cisplatin—germ cell cancer	6.69e-05	0.000568	CcSEcCtD
Nilotinib—ABCG2—bone marrow—germ cell cancer	6.67e-05	0.000571	CbGeAlD
Nilotinib—Diarrhoea—Etoposide—germ cell cancer	6.66e-05	0.000565	CcSEcCtD
Nilotinib—ABCG2—spinal cord—germ cell cancer	6.64e-05	0.000569	CbGeAlD
Nilotinib—Ill-defined disorder—Methotrexate—germ cell cancer	6.63e-05	0.000563	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—germ cell cancer	6.6e-05	0.000561	CcSEcCtD
Nilotinib—ABL1—lymph node—germ cell cancer	6.55e-05	0.000562	CbGeAlD
Nilotinib—CYP2D6—telencephalon—germ cell cancer	6.5e-05	0.000557	CbGeAlD
Nilotinib—CA2—endocrine gland—germ cell cancer	6.46e-05	0.000553	CbGeAlD
Nilotinib—Malaise—Methotrexate—germ cell cancer	6.44e-05	0.000547	CcSEcCtD
Nilotinib—Dizziness—Etoposide—germ cell cancer	6.44e-05	0.000546	CcSEcCtD
Nilotinib—ABCG2—female gonad—germ cell cancer	6.43e-05	0.000551	CbGeAlD
Nilotinib—Vertigo—Methotrexate—germ cell cancer	6.42e-05	0.000545	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—germ cell cancer	6.4e-05	0.000543	CcSEcCtD
Nilotinib—CA2—head—germ cell cancer	6.37e-05	0.000546	CbGeAlD
Nilotinib—CYP2B6—adrenal gland—germ cell cancer	6.36e-05	0.000545	CbGeAlD
Nilotinib—Nausea—Cisplatin—germ cell cancer	6.31e-05	0.000536	CcSEcCtD
Nilotinib—Cough—Methotrexate—germ cell cancer	6.24e-05	0.000529	CcSEcCtD
Nilotinib—Vomiting—Etoposide—germ cell cancer	6.19e-05	0.000525	CcSEcCtD
Nilotinib—CA2—testis—germ cell cancer	6.16e-05	0.000527	CbGeAlD
Nilotinib—CYP2C8—endocrine gland—germ cell cancer	6.15e-05	0.000527	CbGeAlD
Nilotinib—Rash—Etoposide—germ cell cancer	6.14e-05	0.000521	CcSEcCtD
Nilotinib—Dermatitis—Etoposide—germ cell cancer	6.13e-05	0.000521	CcSEcCtD
Nilotinib—Headache—Etoposide—germ cell cancer	6.1e-05	0.000518	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—germ cell cancer	6.08e-05	0.000516	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—germ cell cancer	6.08e-05	0.000516	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—germ cell cancer	6.08e-05	0.000516	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	6.04e-05	0.000513	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—germ cell cancer	6.01e-05	0.00051	CcSEcCtD
Nilotinib—ABCB1—trigeminal ganglion—germ cell cancer	5.95e-05	0.00051	CbGeAlD
Nilotinib—Confusional state—Methotrexate—germ cell cancer	5.88e-05	0.000499	CcSEcCtD
Nilotinib—CYP2C8—testis—germ cell cancer	5.86e-05	0.000502	CbGeAlD
Nilotinib—Infection—Methotrexate—germ cell cancer	5.79e-05	0.000492	CcSEcCtD
Nilotinib—Nausea—Etoposide—germ cell cancer	5.78e-05	0.000491	CcSEcCtD
Nilotinib—ABCB1—embryo—germ cell cancer	5.75e-05	0.000492	CbGeAlD
Nilotinib—Nervous system disorder—Methotrexate—germ cell cancer	5.72e-05	0.000485	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—germ cell cancer	5.71e-05	0.000485	CcSEcCtD
Nilotinib—ABCG2—testis—germ cell cancer	5.7e-05	0.000488	CbGeAlD
Nilotinib—CA2—cerebellum—germ cell cancer	5.69e-05	0.000487	CbGeAlD
Nilotinib—Skin disorder—Methotrexate—germ cell cancer	5.66e-05	0.000481	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—germ cell cancer	5.64e-05	0.000479	CcSEcCtD
Nilotinib—CA4—brain—germ cell cancer	5.57e-05	0.000477	CbGeAlD
Nilotinib—Anorexia—Methotrexate—germ cell cancer	5.56e-05	0.000472	CcSEcCtD
Nilotinib—CYP2B6—endocrine gland—germ cell cancer	5.52e-05	0.000473	CbGeAlD
Nilotinib—CYP2C9—endocrine gland—germ cell cancer	5.46e-05	0.000468	CbGeAlD
Nilotinib—Hypotension—Methotrexate—germ cell cancer	5.45e-05	0.000463	CcSEcCtD
Nilotinib—CYP2B6—head—germ cell cancer	5.45e-05	0.000467	CbGeAlD
Nilotinib—CA4—lymph node—germ cell cancer	5.38e-05	0.000461	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Methotrexate—germ cell cancer	5.31e-05	0.000451	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—germ cell cancer	5.27e-05	0.000448	CcSEcCtD
Nilotinib—ABCG2—cerebellum—germ cell cancer	5.27e-05	0.000451	CbGeAlD
Nilotinib—CYP2B6—testis—germ cell cancer	5.26e-05	0.000451	CbGeAlD
Nilotinib—Paraesthesia—Methotrexate—germ cell cancer	5.24e-05	0.000444	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—germ cell cancer	5.2e-05	0.000441	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—germ cell cancer	5.13e-05	0.000436	CcSEcCtD
Nilotinib—ABCB1—retina—germ cell cancer	5.08e-05	0.000435	CbGeAlD
Nilotinib—Decreased appetite—Methotrexate—germ cell cancer	5.07e-05	0.00043	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—germ cell cancer	5.03e-05	0.000427	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—germ cell cancer	5.03e-05	0.000427	CcSEcCtD
Nilotinib—Pain—Methotrexate—germ cell cancer	4.99e-05	0.000423	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—germ cell cancer	4.81e-05	0.000408	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—germ cell cancer	4.77e-05	0.000405	CcSEcCtD
Nilotinib—ABCB1—telencephalon—germ cell cancer	4.67e-05	0.0004	CbGeAlD
Nilotinib—Urticaria—Methotrexate—germ cell cancer	4.63e-05	0.000393	CcSEcCtD
Nilotinib—CA2—brain—germ cell cancer	4.62e-05	0.000396	CbGeAlD
Nilotinib—Body temperature increased—Methotrexate—germ cell cancer	4.61e-05	0.000391	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—germ cell cancer	4.61e-05	0.000391	CcSEcCtD
Nilotinib—CA2—lymph node—germ cell cancer	4.46e-05	0.000382	CbGeAlD
Nilotinib—ABCB1—decidua—germ cell cancer	4.43e-05	0.00038	CbGeAlD
Nilotinib—CYP2D6—female gonad—germ cell cancer	4.41e-05	0.000378	CbGeAlD
Nilotinib—CYP2C8—brain—germ cell cancer	4.4e-05	0.000377	CbGeAlD
Nilotinib—Hypersensitivity—Methotrexate—germ cell cancer	4.3e-05	0.000365	CcSEcCtD
Nilotinib—ABCG2—brain—germ cell cancer	4.28e-05	0.000366	CbGeAlD
Nilotinib—Asthenia—Methotrexate—germ cell cancer	4.18e-05	0.000355	CcSEcCtD
Nilotinib—CYP3A4—endocrine gland—germ cell cancer	4.17e-05	0.000357	CbGeAlD
Nilotinib—ABCG2—lymph node—germ cell cancer	4.13e-05	0.000354	CbGeAlD
Nilotinib—Pruritus—Methotrexate—germ cell cancer	4.13e-05	0.00035	CcSEcCtD
Nilotinib—CYP2D6—endocrine gland—germ cell cancer	4.1e-05	0.000351	CbGeAlD
Nilotinib—CYP2D6—head—germ cell cancer	4.05e-05	0.000347	CbGeAlD
Nilotinib—Diarrhoea—Methotrexate—germ cell cancer	3.99e-05	0.000339	CcSEcCtD
Nilotinib—CYP2B6—brain—germ cell cancer	3.95e-05	0.000338	CbGeAlD
Nilotinib—CYP2D6—testis—germ cell cancer	3.91e-05	0.000335	CbGeAlD
Nilotinib—ABCB1—gonad—germ cell cancer	3.9e-05	0.000334	CbGeAlD
Nilotinib—ABCB1—uterus—germ cell cancer	3.88e-05	0.000332	CbGeAlD
Nilotinib—Dizziness—Methotrexate—germ cell cancer	3.86e-05	0.000327	CcSEcCtD
Nilotinib—ABCB1—pituitary gland—germ cell cancer	3.81e-05	0.000326	CbGeAlD
Nilotinib—Vomiting—Methotrexate—germ cell cancer	3.71e-05	0.000315	CcSEcCtD
Nilotinib—Rash—Methotrexate—germ cell cancer	3.68e-05	0.000312	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—germ cell cancer	3.67e-05	0.000312	CcSEcCtD
Nilotinib—ABCB1—medulla oblongata—germ cell cancer	3.67e-05	0.000315	CbGeAlD
Nilotinib—Headache—Methotrexate—germ cell cancer	3.65e-05	0.00031	CcSEcCtD
Nilotinib—CYP2D6—cerebellum—germ cell cancer	3.61e-05	0.000309	CbGeAlD
Nilotinib—Nausea—Methotrexate—germ cell cancer	3.46e-05	0.000294	CcSEcCtD
Nilotinib—ABCB1—adrenal gland—germ cell cancer	3.4e-05	0.000291	CbGeAlD
Nilotinib—ABCB1—midbrain—germ cell cancer	3.36e-05	0.000288	CbGeAlD
Nilotinib—ABCB1—bone marrow—germ cell cancer	3.29e-05	0.000282	CbGeAlD
Nilotinib—ABCB1—spinal cord—germ cell cancer	3.28e-05	0.000281	CbGeAlD
Nilotinib—ABCB1—female gonad—germ cell cancer	3.17e-05	0.000272	CbGeAlD
Nilotinib—ABCB1—endocrine gland—germ cell cancer	2.95e-05	0.000253	CbGeAlD
Nilotinib—CYP2D6—brain—germ cell cancer	2.93e-05	0.000251	CbGeAlD
Nilotinib—ABCB1—head—germ cell cancer	2.91e-05	0.000249	CbGeAlD
Nilotinib—ABCB1—testis—germ cell cancer	2.81e-05	0.000241	CbGeAlD
Nilotinib—ABCB1—cerebellum—germ cell cancer	2.6e-05	0.000222	CbGeAlD
Nilotinib—ABCB1—brain—germ cell cancer	2.11e-05	0.000181	CbGeAlD
Nilotinib—ABCB1—lymph node—germ cell cancer	2.04e-05	0.000175	CbGeAlD
Nilotinib—BRAF—Signaling by NGF—HRAS—germ cell cancer	1.43e-05	0.000135	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—KIT—germ cell cancer	1.43e-05	0.000135	CbGpPWpGaD
Nilotinib—HCK—Disease—KIT—germ cell cancer	1.42e-05	0.000134	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FGF4—germ cell cancer	1.41e-05	0.000134	CbGpPWpGaD
Nilotinib—LCK—Downstream signal transduction—HRAS—germ cell cancer	1.41e-05	0.000133	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—KIT—germ cell cancer	1.41e-05	0.000133	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FGF4—germ cell cancer	1.41e-05	0.000133	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR—HRAS—germ cell cancer	1.41e-05	0.000133	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB2—HRAS—germ cell cancer	1.4e-05	0.000132	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—H2AFZ—germ cell cancer	1.39e-05	0.000132	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—KIT—germ cell cancer	1.39e-05	0.000132	CbGpPWpGaD
Nilotinib—BLK—Immune System—KIT—germ cell cancer	1.39e-05	0.000132	CbGpPWpGaD
Nilotinib—LCK—DAP12 signaling—HRAS—germ cell cancer	1.39e-05	0.000131	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KITLG—germ cell cancer	1.39e-05	0.000131	CbGpPWpGaD
Nilotinib—FGR—Immune System—KIT—germ cell cancer	1.39e-05	0.000131	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—KIT—germ cell cancer	1.38e-05	0.00013	CbGpPWpGaD
Nilotinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	1.37e-05	0.000129	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—H2AFZ—germ cell cancer	1.37e-05	0.000129	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—KIT—germ cell cancer	1.36e-05	0.000129	CbGpPWpGaD
Nilotinib—KIT—Disease—KITLG—germ cell cancer	1.36e-05	0.000128	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—OXT—germ cell cancer	1.35e-05	0.000128	CbGpPWpGaD
Nilotinib—MAPK14—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	1.34e-05	0.000127	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KITLG—germ cell cancer	1.32e-05	0.000125	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR in disease—HRAS—germ cell cancer	1.31e-05	0.000124	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—HRAS—germ cell cancer	1.31e-05	0.000124	CbGpPWpGaD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—HRAS—germ cell cancer	1.31e-05	0.000124	CbGpPWpGaD
Nilotinib—KIT—Signaling by NGF—HRAS—germ cell cancer	1.3e-05	0.000123	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR—HRAS—germ cell cancer	1.3e-05	0.000122	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AVP—germ cell cancer	1.29e-05	0.000122	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR in Cancer—HRAS—germ cell cancer	1.29e-05	0.000121	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KITLG—germ cell cancer	1.28e-05	0.000121	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—FGFR3—germ cell cancer	1.28e-05	0.000121	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—OXT—germ cell cancer	1.28e-05	0.000121	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FGF4—germ cell cancer	1.28e-05	0.000121	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CRABP1—germ cell cancer	1.28e-05	0.000121	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—HRAS—germ cell cancer	1.28e-05	0.000121	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FGF4—germ cell cancer	1.27e-05	0.00012	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—H2AFZ—germ cell cancer	1.26e-05	0.000119	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KITLG—germ cell cancer	1.26e-05	0.000119	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—H2AFZ—germ cell cancer	1.26e-05	0.000119	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KITLG—germ cell cancer	1.25e-05	0.000118	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by NGF—HRAS—germ cell cancer	1.23e-05	0.000116	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—FGFR3—germ cell cancer	1.23e-05	0.000116	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AVP—germ cell cancer	1.23e-05	0.000116	CbGpPWpGaD
Nilotinib—LYN—Immune System—KITLG—germ cell cancer	1.23e-05	0.000116	CbGpPWpGaD
Nilotinib—LCK—Immune System—FGF4—germ cell cancer	1.22e-05	0.000115	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KITLG—germ cell cancer	1.22e-05	0.000115	CbGpPWpGaD
Nilotinib—LCK—B Cell Activation—HRAS—germ cell cancer	1.21e-05	0.000114	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—FGFR3—germ cell cancer	1.21e-05	0.000114	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—TP53—germ cell cancer	1.2e-05	0.000113	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—KIT—germ cell cancer	1.18e-05	0.000111	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—SLC2A3—germ cell cancer	1.17e-05	0.00011	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KITLG—germ cell cancer	1.16e-05	0.00011	CbGpPWpGaD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—HRAS—germ cell cancer	1.16e-05	0.000109	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KITLG—germ cell cancer	1.16e-05	0.000109	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGF4—germ cell cancer	1.16e-05	0.000109	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—OXT—germ cell cancer	1.15e-05	0.000109	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—SLC22A3—germ cell cancer	1.15e-05	0.000109	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—TP53—germ cell cancer	1.15e-05	0.000109	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—HRAS—germ cell cancer	1.15e-05	0.000108	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—H2AFZ—germ cell cancer	1.14e-05	0.000108	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—HRAS—germ cell cancer	1.14e-05	0.000108	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—H2AFZ—germ cell cancer	1.13e-05	0.000107	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—KIT—germ cell cancer	1.13e-05	0.000107	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—OXT—germ cell cancer	1.13e-05	0.000107	CbGpPWpGaD
Nilotinib—LCK—Disease—FGF4—germ cell cancer	1.13e-05	0.000107	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—HRAS—germ cell cancer	1.11e-05	0.000105	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—KIT—germ cell cancer	1.11e-05	0.000105	CbGpPWpGaD
Nilotinib—BRAF—Disease—FGFR3—germ cell cancer	1.11e-05	0.000104	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—HRAS—germ cell cancer	1.11e-05	0.000104	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGF4—germ cell cancer	1.09e-05	0.000103	CbGpPWpGaD
Nilotinib—KIT—Immune System—FGFR3—germ cell cancer	1.09e-05	0.000103	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—OXT—germ cell cancer	1.07e-05	0.000101	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KITLG—germ cell cancer	1.05e-05	9.94e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KITLG—germ cell cancer	1.04e-05	9.84e-05	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—HRAS—germ cell cancer	1.03e-05	9.77e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—FGFR3—germ cell cancer	1.03e-05	9.75e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—H2AFZ—germ cell cancer	1.03e-05	9.74e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—HRAS—germ cell cancer	1.03e-05	9.74e-05	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—HRAS—germ cell cancer	1.03e-05	9.73e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AVP—germ cell cancer	1.03e-05	9.71e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AVP—germ cell cancer	1.02e-05	9.62e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—KIT—germ cell cancer	1.02e-05	9.59e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—H2AFZ—germ cell cancer	1.01e-05	9.52e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—FGFR3—germ cell cancer	1.01e-05	9.51e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—KITLG—germ cell cancer	1e-05	9.48e-05	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—HRAS—germ cell cancer	9.93e-06	9.38e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SLC2A3—germ cell cancer	9.9e-06	9.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGF4—germ cell cancer	9.85e-06	9.3e-05	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—HRAS—germ cell cancer	9.85e-06	9.3e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FGFR3—germ cell cancer	9.82e-06	9.27e-05	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—HRAS—germ cell cancer	9.8e-06	9.25e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—H2AFZ—germ cell cancer	9.77e-06	9.22e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SLC22A3—germ cell cancer	9.75e-06	9.2e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGF4—germ cell cancer	9.65e-06	9.11e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—FGFR3—germ cell cancer	9.54e-06	9e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KITLG—germ cell cancer	9.49e-06	8.96e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KIT—germ cell cancer	9.48e-06	8.95e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CRABP1—germ cell cancer	9.39e-06	8.86e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FGFR3—germ cell cancer	9.34e-06	8.81e-05	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—HRAS—germ cell cancer	9.33e-06	8.81e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FGFR3—germ cell cancer	9.3e-06	8.78e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AVP—germ cell cancer	9.28e-06	8.76e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—KITLG—germ cell cancer	9.28e-06	8.76e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—OXT—germ cell cancer	9.26e-06	8.75e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGF4—germ cell cancer	9.14e-06	8.63e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—FGFR3—germ cell cancer	9.11e-06	8.6e-05	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—HRAS—germ cell cancer	9.07e-06	8.56e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FGFR3—germ cell cancer	9.07e-06	8.56e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KIT—germ cell cancer	9.01e-06	8.51e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KITLG—germ cell cancer	8.98e-06	8.48e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—HRAS—germ cell cancer	8.92e-06	8.42e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—H2AFZ—germ cell cancer	8.8e-06	8.31e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AVP—germ cell cancer	8.78e-06	8.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KIT—germ cell cancer	8.75e-06	8.27e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FGFR3—germ cell cancer	8.64e-06	8.15e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SLC2A3—germ cell cancer	8.62e-06	8.14e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—H2AFZ—germ cell cancer	8.61e-06	8.13e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FGFR3—germ cell cancer	8.59e-06	8.11e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KIT—germ cell cancer	8.57e-06	8.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KIT—germ cell cancer	8.54e-06	8.06e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SLC22A3—germ cell cancer	8.49e-06	8.02e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—AVP—germ cell cancer	8.49e-06	8.02e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—KIT—germ cell cancer	8.36e-06	7.9e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KIT—germ cell cancer	8.32e-06	7.86e-05	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—HRAS—germ cell cancer	8.24e-06	7.78e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	8.21e-06	7.76e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—H2AFZ—germ cell cancer	8.17e-06	7.71e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC2A3—germ cell cancer	8.13e-06	7.67e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KITLG—germ cell cancer	8.09e-06	7.64e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC2A3—germ cell cancer	8.06e-06	7.6e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC22A3—germ cell cancer	8e-06	7.56e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CRABP1—germ cell cancer	7.95e-06	7.5e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC22A3—germ cell cancer	7.93e-06	7.49e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KIT—germ cell cancer	7.93e-06	7.49e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KITLG—germ cell cancer	7.92e-06	7.48e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AVP—germ cell cancer	7.91e-06	7.47e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF4—germ cell cancer	7.91e-06	7.46e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KIT—germ cell cancer	7.89e-06	7.45e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FGFR3—germ cell cancer	7.82e-06	7.39e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—MYC—germ cell cancer	7.82e-06	7.38e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FGFR3—germ cell cancer	7.75e-06	7.32e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AVP—germ cell cancer	7.75e-06	7.31e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KITLG—germ cell cancer	7.51e-06	7.09e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—FGFR3—germ cell cancer	7.47e-06	7.05e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—HRAS—germ cell cancer	7.43e-06	7.02e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AVP—germ cell cancer	7.34e-06	6.93e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—germ cell cancer	7.21e-06	6.8e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KIT—germ cell cancer	7.18e-06	6.78e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—germ cell cancer	7.17e-06	6.77e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—HRAS—germ cell cancer	7.14e-06	6.74e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KIT—germ cell cancer	7.12e-06	6.72e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—H2AFZ—germ cell cancer	7.06e-06	6.67e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGFR3—germ cell cancer	7.05e-06	6.66e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—HRAS—germ cell cancer	7.04e-06	6.64e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—HRAS—germ cell cancer	7.03e-06	6.63e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—HRAS—germ cell cancer	6.99e-06	6.6e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CRABP1—germ cell cancer	6.92e-06	6.54e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—FGFR3—germ cell cancer	6.89e-06	6.51e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—HRAS—germ cell cancer	6.89e-06	6.51e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—HRAS—germ cell cancer	6.86e-06	6.48e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—KIT—germ cell cancer	6.86e-06	6.47e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—germ cell cancer	6.83e-06	6.45e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—HRAS—germ cell cancer	6.76e-06	6.38e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	6.75e-06	6.37e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGFR3—germ cell cancer	6.68e-06	6.3e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—HRAS—germ cell cancer	6.66e-06	6.29e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—HRAS—germ cell cancer	6.65e-06	6.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—HRAS—germ cell cancer	6.53e-06	6.17e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CRABP1—germ cell cancer	6.52e-06	6.16e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KITLG—germ cell cancer	6.5e-06	6.13e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CRABP1—germ cell cancer	6.47e-06	6.11e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AVP—germ cell cancer	6.35e-06	5.99e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—HRAS—germ cell cancer	6.34e-06	5.98e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—KIT—germ cell cancer	6.33e-06	5.98e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—HRAS—germ cell cancer	6.21e-06	5.86e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—HRAS—germ cell cancer	6.18e-06	5.83e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—HRAS—germ cell cancer	6.14e-06	5.8e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KIT—germ cell cancer	6.13e-06	5.79e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HRAS—germ cell cancer	6.09e-06	5.75e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—MYC—germ cell cancer	6.08e-06	5.74e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—HRAS—germ cell cancer	6.03e-06	5.69e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HRAS—germ cell cancer	6.03e-06	5.69e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGFR3—germ cell cancer	6.02e-06	5.68e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—HRAS—germ cell cancer	6.01e-06	5.67e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HRAS—germ cell cancer	5.96e-06	5.63e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—germ cell cancer	5.91e-06	5.58e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGFR3—germ cell cancer	5.89e-06	5.56e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—HRAS—germ cell cancer	5.88e-06	5.55e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—HRAS—germ cell cancer	5.65e-06	5.33e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MYC—germ cell cancer	5.59e-06	5.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGFR3—germ cell cancer	5.58e-06	5.27e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KIT—germ cell cancer	5.52e-06	5.21e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KIT—germ cell cancer	5.41e-06	5.11e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A3—germ cell cancer	5.31e-06	5.02e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC22A3—germ cell cancer	5.23e-06	4.94e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KIT—germ cell cancer	5.13e-06	4.84e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MYC—germ cell cancer	5.09e-06	4.8e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—HRAS—germ cell cancer	5.09e-06	4.8e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MYC—germ cell cancer	4.96e-06	4.68e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HRAS—germ cell cancer	4.88e-06	4.61e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGFR3—germ cell cancer	4.83e-06	4.56e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MYC—germ cell cancer	4.82e-06	4.55e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HRAS—germ cell cancer	4.8e-06	4.53e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MYC—germ cell cancer	4.72e-06	4.45e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KIT—germ cell cancer	4.43e-06	4.18e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—HRAS—germ cell cancer	4.39e-06	4.15e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—germ cell cancer	4.34e-06	4.1e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—germ cell cancer	4.34e-06	4.1e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—HRAS—germ cell cancer	4.33e-06	4.09e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CRABP1—germ cell cancer	4.27e-06	4.03e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—germ cell cancer	4.1e-06	3.87e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—germ cell cancer	4.07e-06	3.85e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—germ cell cancer	4e-06	3.77e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—germ cell cancer	3.95e-06	3.73e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—germ cell cancer	3.92e-06	3.7e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—germ cell cancer	3.9e-06	3.68e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—germ cell cancer	3.87e-06	3.66e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—germ cell cancer	3.78e-06	3.57e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—germ cell cancer	3.7e-06	3.5e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—germ cell cancer	3.69e-06	3.49e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—germ cell cancer	3.61e-06	3.41e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—germ cell cancer	3.6e-06	3.4e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—germ cell cancer	3.56e-06	3.36e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—germ cell cancer	3.48e-06	3.29e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—germ cell cancer	3.43e-06	3.23e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—germ cell cancer	3.41e-06	3.22e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—germ cell cancer	3.37e-06	3.18e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—germ cell cancer	3.25e-06	3.06e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—germ cell cancer	3.22e-06	3.04e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—germ cell cancer	3.1e-06	2.93e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—germ cell cancer	3.07e-06	2.9e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—germ cell cancer	3.04e-06	2.87e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—germ cell cancer	2.98e-06	2.81e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—germ cell cancer	2.96e-06	2.8e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—germ cell cancer	2.93e-06	2.76e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—germ cell cancer	2.82e-06	2.66e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—germ cell cancer	2.8e-06	2.64e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—germ cell cancer	2.77e-06	2.62e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—germ cell cancer	2.74e-06	2.58e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—germ cell cancer	2.65e-06	2.5e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—germ cell cancer	2.5e-06	2.36e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—germ cell cancer	2.44e-06	2.31e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—germ cell cancer	2.44e-06	2.3e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—germ cell cancer	2.39e-06	2.25e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—germ cell cancer	2.34e-06	2.21e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—germ cell cancer	2.32e-06	2.19e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—germ cell cancer	2.22e-06	2.09e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—germ cell cancer	2e-06	1.89e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—germ cell cancer	1.92e-06	1.81e-05	CbGpPWpGaD
